— Improvements in both serum liver enzymes and liver imaging — Improvement in serum lipid profile — DUR-928 was well tolerated with no significant adverse events — Promising data support further development of DUR-928 in NASH CUPERTINO, Calif., May 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced positive topline results from its Phase 1b […]
Working on Proof-of-Concept Phase 2 Trial in COVID-19 Patients with Acute Liver or Kidney Injury Live Webcast of Earnings Call Today, May 11th at 4:30 p.m. ET CUPERTINO, Calif., May 11, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2020 and provided a corporate update.
DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs Read More »
CUPERTINO, Calif., May 4, 2020 DURECT Corporation (Nasdaq: DRRX) today announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, May 11, 2020. Monday May 11th @ 4:30pm Eastern Time/ 1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13703442 Webcast: http://public.viavid.com/index.php?id=139763 About DURECT Corporation
Fourth Quarter Highlighted by Presentation of Positive DUR-928 Phase 2a Alcoholic Hepatitis Data at the Liver Meeting® 2019 Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 3, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2019 and
CUPERTINO, Calif., Feb. 26, 2020 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results and host a conference call after the market close on Tuesday, March 3, 2020. Tuesday March 3rd @ 4:30pmET/1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560
DURECT Corporation to Announce 2019 Financial Results on March 3 Read More »
CUPERTINO, Calif., Jan. 17, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met yesterday to discuss the Class 2 New Drug Application (NDA) resubmission for POSIMIR® (bupivacaine extended-release solution). In a split vote on the key question, six
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR® Read More »
CUPERTINO, Calif., Jan. 16, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that NASDAQ has halted trading of the Company’s common stock today. The U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is holding a meeting today from 8 a.m. to 5 p.m. ET to discuss POSIMIR, an investigational
CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928 topically to the plaque on one arm and the vehicle (placebo) to a similar plaque on the other arm
CUPERTINO, Calif., Nov. 15, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Stifel 2019 Health Care Conference, at the Lotte New York Palace Hotel on Tuesday, November 19, 2019 at 3:35 p.m. EST. Institutional investors and analysts that are attending the conference may request
DURECT to Present at the Stifel 2019 Health Care Conference Read More »
Live Webcast of Data Presentation and Discussion by KOL, Tarek I. Hassanein, M.D. at Noon ET on Tuesday, November 12, 2019 CUPERTINO, Calif., Nov. 12, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in alcoholic hepatitis (AH), presented as a late-breaking oral presentation at The Liver
